J7682Tobramycin non-comp unit
Published CMS Medicare Part B payment-limit context for J7682, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$12.305
per 300 MG · Medicare Part B
Up 58.4%from $7.766 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$17.399$6.583
2024-Q4: $15.952; 2025-Q1: $16.003; 2025-Q2: $14.803; 2025-Q3: $14.457; 2025-Q4: $16.216; 2026-Q1: $12.47; 2026-Q2: $7.766; 2026-Q3: $12.305
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Tobramycin ingredient family (FDA data as of August 20, 2026).
Tobramycin
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Tobramycin presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J3260 | Tobramycin sulfate injection | $2.186 per 80 MG | $2.019 per 80 MG | Up 8.3% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.